Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scient...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2e783d06a91c488f9fb5a86eeb213adf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|